EMBECTA CORP

Embecta insider buying by CEO Devdatt signals confidence amid a sharp rally and 62% drop from its peak, hinting at possible upside if fundamentals strengthen.

Cas Jean’s insider sale of 1,480 Embecta shares shows a routine portfolio shift, not a warning—while FDA‑cleared CGM success and solid fundamentals keep the company on track.

Insider buying signals Embecta’s undervalued stock after FDA/EMA approval of its CGM sensor, showing strong safety data, low P/E, and growth potential.